Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases

Journal of Ethnopharmacology

Volumn 210, Issue , 2018, Pages 296-310

  Eng, Qian Yi ^a   Thanikachalam, Punniyakoti Veeraveedu ^a   Ramamurthy, Srinivasan ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Anti inflammatory; Antioxidant; Atherosclerosis; Diabetes; EGCG; Heart failure

Indexed keywords

EPIGALLOCATECHIN GALLATE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; REACTIVE OXYGEN METABOLITE; ANTIINFLAMMATORY AGENT; CARDIOVASCULAR AGENT; CATECHIN;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BIBLIOGRAPHIC DATABASE; BRAIN ISCHEMIA; CAMELLIA SINENSIS; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG METABOLISM; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; PRECLINICAL STUDY; REVIEW; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; ISOLATION AND PURIFICATION; PATHOPHYSIOLOGY; TEA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CAMELLIA SINENSIS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CATECHIN; HUMANS; METABOLIC DISEASES; TEA;

EID: 85028917658     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2017.08.035     Document Type: Review

References (126)

1. Alberti, K.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet. Med. 15 (1998), 539–553, 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.
2. American Diabetes Association, A.D., Diagnosis and classification of diabetes mellitus. Diabetes Care 33:Suppl. 1 (2010), S62–S69, 10.2337/dc10-S062.
3. Aneja, R., Hake, P.W., Burroughs, T.J., Denenberg, A.G., Wong, H.R., Zingarelli, B., Epigallocatechin, a green tea polyphenol, attenuates myocardial ischemia reperfusion injury in rats. Mol. Med. 10 (2004), 55–62.
4. Anversa, P., Palackal, T., Sonnenblick, E.H., Olivetti, G., Meggs, L.G., Capasso, J.M., Myocyte cell loss and myocyte cellular hyperplasia in the hypertrophied aging rat heart. Circ. Res. 67 (1990), 871–885, 10.1161/01.RES.67.4.871.
5. Aree, T., Jongrungruangchok, S., Enhancement of antioxidant activity of green tea epicatechins in β-cyclodextrin cavity: single-crystal X-ray analysis, DFT calculation and DPPH assay. Carbohydr. Polym. 151 (2016), 1139–1151, 10.1016/j.carbpol.2016.05.113.
6. Arffa, M.L., Zapf, M.A., Kothari, A.N., Chang, V., Gupta, G.N., Ding, X., Al-Gayyar, M.M., Syn, W., Elsherbiny, N.M., Kuo, P.C., Mi, Z., Epigallocatechin-3-Gallate upregulates miR-221 to inhibit osteopontin-dependent hepatic fibrosis. PLoS One, 11, 2016, e0167435, 10.1371/journal.pone.0167435.
7. aus dem Siepen, F., Bauer, R., Aurich, M., Buss, S.J., Steen, H., Altland, K., Katus, H.A., Kristen, A.V., Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des. Dev. Ther. 9 (2015), 6319–6325, 10.2147/DDDT.S96893.
8. Boschmann, M., Thielecke, F., The effects of epigallocatechin-3-gallate on thermogenesis and fat oxidation in obese men: a pilot study. J. Am. Coll. Nutr. 26 (2007), 389S–395S.
9. Brewer, M.S., Natural antioxidants: sources, compounds, mechanisms of action, and potential applications. Compr. Rev. Food Sci. Food Saf. 10 (2011), 221–247, 10.1111/j.1541-4337.2011.00156.x.
10. Brown, A.L., Lane, J., Coverly, J., Stocks, J., Jackson, S., Stephen, A., Bluck, L., Coward, A., Hendrickx, H., Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br. J. Nutr. 101 (2009), 886–894, 10.1017/S0007114508047727.
11. Cai, Y., Kurita-Ochiai, T., Hashizume, T., Yamamoto, M., Green tea epigallocatechin-3-gallate attenuates Porphyromonas gingivalis-induced atherosclerosis. Pathog. Dis. 67 (2013), 76–83, 10.1111/2049-632X.12001.
12. Cai, Y., Yu, S.S., Chen, T.T., Gao, S., Geng, B., Yu, Y., Ye, J.T., Liu, P.Q., EGCG inhibits CTGF expression via blocking NF-κB activation in cardiac fibroblast. Phytomedicine 20 (2013), 106–113, 10.1016/j.phymed.2012.10.002.
13. Cai, Y., Zhao, L., Qin, Y., Wu, X.Q., EGCG blocked phenylephrin-induced hypertrophy in H9C2 cardiomyocytes, by activating AMPK-dependent pathway. Korean J. Physiol. Pharmacol. 19 (2015), 203–210, 10.4196/kjpp.2015.19.3.203.
14. Cavet, M.E., Harrington, K.L., Vollmer, T.R., Ward, K.W., Zhang, J.-Z., Anti-inflammatory and anti-oxidative effects of the green tea polyphenol epigallocatechin gallate in human corneal epithelial cells. Mol. Vis. 17 (2011), 533–542.
15. Chacko, S.M., Thambi, P.T., Kuttan, R., Nishigaki, I., Beneficial effects of green tea: a literature review. Chin. Med. 5 (2010), 1–9, 10.1186/1749-8546-5-13.
16. Chang, J.H., Chang, S.L., Hong, P.D., Chen, P.N., Hsu, C.H., Lu, Y.Y., Chen, Y.C., Epigallocatechin-3-gallate modulates arrhythmogenic activity and calcium homeostasis of left atrium. Int. J. Cardiol. 236 (2017), 174–180, 10.1016/j.ijcard.2017.01.090.
17. Chen, A., Zhang, L., The antioxidant (-)-epigallocatechin-3-gallate inhibits rat hepatic stellate cell proliferation in vitro by blocking the tyrosine phosphorylation and reducing the gene expression of platelet-derived growth factor-beta receptor. J. Biol. Chem. 278 (2003), 23381–23389, 10.1074/jbc.M212042200.
18. Chow, H.H., Cai, Y., Hakim, I.A., Crowell, J.A., Shahi, F., Brooks, C.A., Dorr, R.T., Hara, Y., Alberts, D.S., Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin. Cancer Res. 9 (2003), 3312–3319.
19. Chowdhury, A., Nandy, S.K., Sarkar, J., Chakraborti, T., Chakraborti, S., Inhibition of pro-/active MMP-2 by green tea catechins and prediction of their interaction by molecular docking studies. Mol. Cell Biochem. 427 (2017), 111–122, 10.1007/s11010-016-2903-y.
20. Cooper, R., Morré, D.J., Morré, D.M., Medicinal benefits of green tea: part I. Review of noncancer health benefits. J. Altern. Complement. Med. 11 (2005), 521–528, 10.1089/acm.2005.11.521.
21. Cui, W., Mao, W., Du, H., Li, N., Inhibitory effect of tea polyphenols and EGCG on cultured hypertrophic myocyte induced by Ang II. Wei Sheng Yan Jiu 37 (2008), 356–358.
22. Devika, P.T., Prince, P.S.M., (-)-Epigallocatechin gallate (EGCG) prevents isoprenaline-induced cardiac toxicity by stabilizing cardiac marker enzymes and membrane-bound ATPases. J. Pharm. Pharmacol. 60 (2008), 125–133, 10.1211/jpp.60.1.0016.
23. Dorn, G.W., The fuzzy logic of physiological cardiac hypertrophy. Hypertension 49 (2007), 962–970, 10.1161/HYPERTENSIONAHA.106.079426.
24. Eltzschig, H.K., Collard, C.D., Vascular ischaemia and reperfusion injury. Br. Med. Bull. 70 (2004), 71–86, 10.1093/bmb/ldh025.
25. European, E., Union, E., Life-years, D.A., Cardiovascular disease in Europe 2016: an epidemiological update. Eur. Heart J. 37 (2016), 3182–3183, 10.1093/eurheartj/ehw468.
26. Feng, W.Y., Metabolism of green tea catechins: an overview. Curr. Drug Metab. 7 (2006), 755–809.
27. Frey, N., Katus, H.A., Olson, E.N., Hill, J.A., Hypertrophy of the Heart: a new therapeutic target?. Circulation 109 (2004), 1580–1589, 10.1161/01.CIR.0000120390.68287.BB.
28. Friedrich, F.W., Flenner, F., Nasib, M., Eschenhagen, T., Carrier, L., Epigallocatechin-3-gallate accelerates relaxation and Ca(2+) transient decay and desensitizes myofilaments in healthy and Mybpc3-targeted knock-in cardiomyopathic mice. Front. Physiol., 7, 2016, 607, 10.3389/fphys.2016.00607.
29. Friedrich, M., Petzke, K.J., Raederstorff, D., Wolfram, S., Klaus, S., Acute effects of epigallocatechin gallate from green tea on oxidation and tissue incorporation of dietary lipids in mice fed a high-fat diet. Int. J. Obes. 36 (2012), 735–743, 10.1038/ijo.2011.136.
30. Fu, Z., Zhen, W., Yuskavage, J., Liu, D., Epigallocatechin gallate delays the onset of type 1 diabetes in spontaneous non-obese diabetic mice. Br. J. Nutr. 105 (2011), 1218–1225, 10.1017/S0007114510004824.
31. Go, A.S., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127 (2013), e6–e245, 10.1161/CIR.0b013e31828124ad.
32. Hansson, G.K., Atherosclerosis – an immune disease: Anitschkov lecture 2007. Atherosclerosis 202 (2009), 2–10, 10.1016/j.atherosclerosis.2008.08.039.
33. Hao, J., Kim, C.H., Ha, T.S., Ahn, H.Y., Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J. Vet. Sci. 8 (2007), 121–129, 10.4142/jvs.2007.8.2.121.
34. Higashi, N., Kohjima, M., Fukushima, M., Ohta, S., Kotoh, K., Enjoji, M., Kobayashi, N., Nakamuta, M., Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells. J. Lab. Clin. Med. 145 (2005), 316–322, 10.1016/j.lab.2005.03.017.
35. Hill, A.M., Coates, A.M., Buckley, J.D., Ross, R., Thielecke, F., Howe, P.R.C., Can EGCG reduce abdominal fat in obese subjects?. J. Am. Coll. Nutr. 26 (2007), 396S–402S.
36. Hodgson, A.B., Randell, R.K., Boon, N., Garczarek, U., Mela, D.J., Jeukendrup, A.E., Jacobs, D.M., Metabolic response to green tea extract during rest and moderate-intensity exercise. J. Nutr. Biochem. 24 (2013), 325–334, 10.1016/j.jnutbio.2012.06.017.
37. Hsu, C.H., Liao, Y.L., Lin, S.C., Tsai, T.H., Huang, C.J., Chou, P., Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial. Altern. Med Rev. 16 (2011), 157–163, 10.1016/j.ctim.2016.03.004.
38. Hu, C., Kitts, D.D., Evaluation of antioxidant activity of epigallocatechin gallate in biphasic model systems in vitro. Mol. Cell. Biochem. 218 (2001), 147–155, 10.1023/A:1007220928446.
39. Hu, J., Zhou, D., Chen, Y., Preparation and antioxidant activity of green tea extract enriched in epigallocatechin (EGC) and epigallocatechin gallate (EGCG). J. Agric. Food Chem. 57 (2009), 1349–1353, 10.1021/jf803143n.
40. Isbrucker, R.A., Edwards, J.A., Wolz, E., Davidovich, A., Bausch, J., Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem. Toxicol. 44 (2006), 636–650, 10.1016/j.fct.2005.11.003.
41. Ischemia/Reperfusion Injury: R&D Systems A Biotechne Brand. URL 〈 https://www.rndsystems.com/resources/articles/ischemia-reperfusion-injury〉 (accessed on 23 Feburary 2017).
42. Jaffe, A.S., Third universal definition of myocardial infarction. Clin. Biochem. 46 (2013), 1–4, 10.1016/j.clinbiochem.2012.10.036.
43. Johnson, M.K., Loo, G., Effects of epigallocatechin gallate and quercetin on oxidative damage to cellular DNA. Mutat. Res. 459 (2000), 211–218.
44. Kanlaya, R., Khamchun, S., Kapincharanon, C., Thongboonkerd, V., Protective effect of epigallocatechin-3-gallate (EGCG) via Nrf2 pathway against oxalate-induced epithelial mesenchymal transition (EMT) of renal tubular cells. Sci. Rep., 6, 2016, 30233, 10.1038/srep30233.
45. Karori, S.M., Wachira, F.N., Wanyoko, J.K., Ngure, R.M., Antioxidant capacity of different types of tea products. Afr. J. Biotechnol. 6 (2007), 2287–2296.
46. Katholi, R.E., Couri, D.M., Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int. J. Hypertens., 2011, 2011, 495349, 10.4061/2011/495349.
47. Katiyar, S.K., Matsui, M.S., Elmets, C.A., Mukhtar, H., Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea reduces UVB-induced inflammatory responses and infiltration of leukocytes in human skin. Photochem. Photobiol. 69 (1999), 148–153.
48. Khalatbary, A.R., Ahmadvand, H., Anti-inflammatory effect of the epigallocatechin gallate following spinal cord trauma in rat. Iran. Biomed. J. 15 (2011), 31–37.
49. Kim, C.J., Kim, J.M., Lee, S.R., Jang, Y.H., Kim, J.H., Chun, K.J., Polyphenol (-)-epigallocatechin gallate targeting myocardial reperfusion limits infarct size and improves cardiac function. Korean J. Anesthesiol. 58 (2010), 169–175, 10.4097/kjae.2010.58.2.169.
50. Kim, J.J.Y., Tan, Y., Xiao, L., Sun, Y.L., Qu, X., Green tea polyphenol epigallocatechin-3-gallate enhance glycogen synthesis and inhibit lipogenesis in hepatocytes. Biomed. Res. Int. 2013 (2013), 1–8, 10.1155/2013/920128.
51. Klaus, S., Pültz, S., Thöne-Reineke, C., Wolfram, S., Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. Int. J. Obes. 29 (2005), 615–623, 10.1038/sj.ijo.0802926.
52. Kohri, T., Suzuki, M., Nanjo, F., Identification of metabolites of (-)-epicatechin gallate and their metabolic fate in the rat. J. Agric. Food Chem. 51 (2003), 5561–5566, 10.1021/jf034450x.
53. Kumazoe, M., Nakamura, Y., Yamashita, M., Suzuki, T., Takamatsu, K., Huang, Y., Bae, J., Yamashita, S., Murata, M., Yamada, S., Shinoda, Y., Yamaguchi, W., Toyoda, Y., Tachibana, H., Green tea polyphenol epigallocatechin-3-gallate suppresses toll-like receptor 4 expression via upregulation of E3 ubiquitin-protein Ligase RNF216. J. Biol. Chem. 292 (2017), 4077–4088, 10.1074/jbc.M116.755959.
54. Lambert, J.D., Kennett, M.J., Sang, S., Reuhl, K.R., Ju, J., Yang, C.S., Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem. Toxicol. 48 (2010), 409–416, 10.1016/j.fct.2009.10.030.
55. Lee, H., Bae, J.H., Lee, S.R., Protective effect of green tea polyphenol EGCG against neuronal damage and brain edema after unilateral cerebral ischemia in gerbils. J. Neurosci. Res. 77 (2004), 892–900, 10.1002/jnr.20193.
56. Lee, M.S., Kim, C.T., Kim, Y., Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice. Ann. Nutr. Metab. 54 (2009), 151–157, 10.1159/000214834.
57. Lee, S.K., Kim, J.H., Kim, J.S., Jang, Y., Kim, J., Park, Y.H., Chun, K.J., Lee, M.Y., Polyphenol (-)-epigallocatechin gallate-induced cardioprotection may attenuate ischemia-reperfusion injury through adenosine receptor activation: a preliminary study. Korean J. Anesthesiol. 63 (2012), 340–345, 10.4097/kjae.2012.63.4.340.
58. de Leiris, J., Harding, D.P., Pestre, S., The isolated perfused rat heart: a model for studying myocardial hypoxia or ischaemia. Basic Res. Cardiol. 79 (1984), 313–321, 10.1007/BF01908032.
59. Li, C., Lee, M.J., Sheng, S., Meng, X., Prabhu, S., Winnik, B., Huang, B., Chung, J.Y., Yan, S., Ho, C.T., Yang, C.S., Structural identification of two metabolites of catechins and their kinetics in human urine and blood after tea ingestion. Chem. Res. Toxicol. 13 (2000), 177–184.
60. Li, T., Liu, J., Zhang, X., Ji, G., Antidiabetic activity of lipophilic (-)-epigallocatechin-3-gallate derivative under its role of α-glucosidase inhibition. Biomed. Pharmacother. 61 (2007), 91–96, 10.1016/j.biopha.2006.11.002.
61. Liang, R., Chen, L., Yokoyama, W., Williams, P.A., Zhong, F., Niosomes consisting of tween-60 and cholesterol improve the chemical stability and antioxidant activity of (-)-epigallocatechin gallate under intestinal tract conditions. J. Agric. Food Chem. 64 (2016), 9180–9188, 10.1021/acs.jafc.6b04147.
62. Lin, C.L., Lin, J.K., Epigallocatechin gallate (EGCG) attenuates high glucose-induced insulin signaling blockade in human hepG2 hepatoma cells. Mol. Nutr. Food Res. 52 (2008), 930–939, 10.1002/mnfr.200700437.
63. Lin, C.M., Chang, H., Wang, B.-W., Shyu, K.G., Suppressive effect of epigallocatechin-3-O-gallate on endoglin molecular regulation in myocardial fibrosis in vitro and in vivo. J. Cell. Mol. Med. 20 (2016), 2045–2055, 10.1111/jcmm.12895.
64. Liu, D., Perkins, J.T., Hennig, B., EGCG prevents PCB-126-induced endothelial cell inflammation via epigenetic modifications of NF-κB target genes in human endothelial cells. J. Nutr. Biochem. 28 (2016), 164–170, 10.1016/j.jnutbio.2015.10.003.
65. Lobo, V., Patil, A., Phatak, A., Chandra, N., Free radicals, antioxidants and functional foods: impact on human health. Pharmacogn. Rev. 4 (2010), 118–126, 10.4103/0973-7847.70902.
66. Lombo, C., Morgado, C., Tavares, I., Neves, D., Effects of prolonged ingestion of epigallocatechin gallate on diabetes type 1-induced vascular modifications in the erectile tissue of rats. Int. J. Impot. Res. 28 (2016), 133–138, 10.1038/ijir.2016.19.
67. Lyon, R.C., Zanella, F., Omens, J.H., Sheikh, F., Mechanotransduction in cardiac hypertrophy and failure. Circ. Res. 116 (2015), 1462–1476, 10.1161/CIRCRESAHA.116.304937.
68. Machlin, L.J., Bendich, A., Free radical tissue damage: protective role of antioxidant nutrients. FASEB J. 1 (1987), 441–445.
69. Matsuzaki, S., Darcha, C., Antifibrotic properties of epigallocatechin-3-gallate in endometriosis. Hum. Reprod. 29 (2014), 1677–1687, 10.1093/humrep/deu123.
70. Mazzanti, G., Menniti-Ippolito, F., Moro, P.A., Cassetti, F., Raschetti, R., Santuccio, C., Mastrangelo, S., Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur. J. Clin. Pharmacol. 65 (2009), 331–341, 10.1007/s00228-008-0610-7.
71. Meng, M., Li, Y.Q., Yan, M.-X., Kou, Y., Ren, H.-B., Effects of epigallocatechin gallate on diethyldithiocarbamate-induced pancreatic fibrosis in rats. Biol. Pharm. Bull. 30 (2007), 1091–1096.
72. Mereles, D., Hunstein, W., Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises?. Int. J. Mol. Sci. 12 (2011), 5592–5603, 10.3390/ijms12095592.
73. Mielgo-Ayuso, J., Barrenechea, L., Alcorta, P., Larrarte, E., Margareto, J., Labayen, I., Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial. Br. J. Nutr. 111 (2014), 1263–1271, 10.1017/S0007114513003784.
74. Miura, Y., Chiba, T., Tomita, I., Koizumi, H., Miura, S., Umegaki, K., Hara, Y., Ikeda, M., Tomita, T., Tea catechins prevent the development of atherosclerosis in apoprotein E-deficient mice. J. Nutr. 131 (2001), 27–32.
75. Momose, Y., Maeda-Yamamoto, M., Nabetanim, H., Systematic review of green tea epigallocatechin gallate in reducing low-density lipoprotein cholesterol levels of humans. Int. Food Sci. Nutr. 67 (2016), 606–613, 10.1080/09637486.2016.1196655.
76. Nagle, D.G., Ferreira, D., Zhou, Y.D., Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry 67 (2006), 1849–1855, 10.1016/j.phytochem.2006.06.020.
77. Nakagawa, K., Miyazawa, T., Absorption and distribution of tea catechin, (-)-epigallocatechin-3-gallate, in the rat. J. Nutr. Sci. Vitaminol. 43 (1997), 679–684.
78. Nakagawa, K., Okuda, S., Miyazawa, T., Dose-dependent incorporation of tea catechins, (-)-epigallocatechin-3-gallate and (-)-epigallocatechin, into human plasma. Biosci. Biotechnol. Biochem. 61 (1997), 1981–1985.
79. Nakamuta, M., Higashi, N., Kohjima, M., Fukushima, M., Ohta, S., Kotoh, K., Kobayashi, N., Enjoji, M., Epigallocatechin-3-gallate, a polyphenol component of green tea, suppresses both collagen production and collagenase activity in hepatic stellate cells. Int. J. Mol. Med. 16 (2005), 677–681.
80. Naumovski, N., Blades, B.L., Roach, P.D., Food inhibits the oral bioavailability of the major green tea antioxidant Epigallocatechin gallate in humans. Antioxidants 4 (2015), 373–933, 10.3390/antiox4020373.
81. Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 (2007), 2457–2471, 10.1056/NEJMoa072761.
82. Othman, A.I., Elkomy, M.M., El-Missiry, M.A., Dardor, M., Epigallocatechin-3-gallate prevents cardiac apoptosis by modulating the intrinsic apoptotic pathway in isoproterenol-induced myocardial infarction. Eur. J. Pharmacol. 794 (2017), 27–36, 10.1016/j.ejphar.2016.11.014.
83. Othman, A.I., El-Sawi, M.R., El-Missiry, M.A., Abukhalil, M.H., Epigallocatechin-3 gallate protects against diabetic cardiomyopathy through modulating the cardio metabolic risk factors, oxidative stress, inflammation, cell death and fibrosis in streptozotocin-nicotinamide induced diabetic rats. Biomed. Pharmacother. 94 (2017), 362–373, 10.1016/j.biopha.2017.07.129.
84. Oyama, J., Shiraki, A., Nishikido, T., Maeda, T., Komoda, H., Shimizu, T., Makino, N., Node, K., EGCG, a green tea catechin, attenuates the progression of heart failure induced by the heart/muscle-specific deletion of MnSOD in mice. J. Cardiol. 69 (2017), 417–427, 10.1016/j.jjcc.2016.05.019.
85. Pan, B., Quan, J., Liu, L., Xu, Z., Zhu, J., Huang, X., Tian, J., Epigallocatechin gallate reverses cTnI-low expression-induced age-related heart diastolic dysfunction through histone acetylation modification. J. Cell. Mol. Med., 2017, 10.1111/jcmm.13169.
86. Park, J.W., Jang, Y.H., Kim, J.M., Lee, H., Park, W.K., Lim, M.B., Chu, Y.K., Lo, E.H., Lee, S.R., Green tea polyphenol (-)-epigallocatechin gallate reduces neuronal cell damage and up-regulation of MMP-9 activity in hippocampal CA1 and CA2 areas following transient global cerebral ischemia. J. Neurosci. Res. 87 (2009), 567–575, 10.1002/jnr.21847.
87. Pastore, R.L., Fratellone, P., Potential health benefits of green tea (Camellia sinensis): a narrative review. Explor. J. Sci. Heal. 2 (2006), 531–539, 10.1016/j.explore.2006.08.008.
88. Ramesh, E., Geraldine, P., Thomas, P.A., Regulatory effect of epigallocatechin gallate on the expression of C-reactive protein and other inflammatory markers in an experimental model of atherosclerosis. Chem. Biol. Interact. 183 (2010), 125–132, 10.1016/j.cbi.2009.09.013.
89. Robertson, S., What is Fibrosis? URL 〈http://www.news-medical.net/health/What-is-Fibrosis.aspx〉 (accessed on 23 Feburary 2017).
90. Sampath, C., Sang, S., Ahmedna, M., In vitro and in vivo inhibition of aldose reductase and advanced glycation end products by phloretin, epigallocatechin 3-gallate and [6]-gingerol. Biomed. Pharmacother. 84 (2016), 502–513, 10.1016/j.biopha.2016.09.073.
91. Shah, A.S., Dolan, L.M., Gao, Z., Kimball, T.R., Urbina, E.M., Clustering of risk factors: a simple method of detecting cardiovascular disease in youth. Pediatrics 127 (2011), e312–e318, 10.1542/peds.2010-1125.
92. Sharma, P., Jha, A.B., Dubey, R.S., Pessarakli, M., Reactive oxygen species, oxidative damage, and antioxidative defense mechanism in plants under stressful conditions. J. Bot. 2012 (2012), 1–26, 10.1155/2012/217037.
93. Sheng, R., Gu, Z., Xie, M., Zhou, W., Guo, C., EGCG inhibits proliferation of cardiac fibroblasts in rats with cardiac hypertrophy. Planta Med. 75 (2009), 113–120, 10.1055/s-0028-1088387.
94. Sheng, R., Gu, Z.-L., Xie, M.-L., Epigallocatechin gallate, the major component of polyphenols in green tea, inhibits telomere attrition mediated cardiomyocyte apoptosis in cardiac hypertrophy. Int. J. Cardiol. 162 (2013), 199–209, 10.1016/j.ijcard.2011.07.083.
95. Shimizu, I., Minamino, T., Physiological and pathological cardiac hypertrophy. J. Mol. Cell. Cardiol. 97 (2016), 245–262, 10.1016/j.yjmcc.2016.06.001.
96. Song, D.K., Jang, Y., Kim, J.H., Chun, K.J., Lee, D., Xu, Z., Polyphenol (-)-epigallocatechin gallate during ischemia limits infarct size via mitochondrial K(ATP) channel activation in isolated rat hearts. J. Korean Med. Sci. 25 (2010), 380–386, 10.3346/jkms.2010.25.3.380.
97. Song, E.K., Hur, H., Han, M.-K., Epigallocatechin gallate prevents autoimmune diabetes induced by multiple low doses of streptozotocin in mice. Arch. Pharm. Res. 26 (2003), 559–563.
98. Song, Y., Manson, J.E., Buring, J.E., Sesso, H.D., Liu, S., Associations of dietary flavonoids with risk of type 2 diabetes, and markers of insulin resistance and systemic inflammation in women: a prospective study and cross-sectional analysis. J. Am. Coll. Nutr. 24 (2005), 376–384, 10.1080/07315724.2005.10719488.
99. Sriram, N., Kalayarasan, S., Sudhandiran, G., Enhancement of antioxidant defense system by epigallocatechin-3-gallate during bleomycin induced experimental pulmonary fibrosis. Biol. Pharm. Bull. 31 (2008), 1306–1311, 10.1248/bpb.31.1306.
100. Stankov, S.V., Definition of inflammation, causes of inflammation and possible anti-inflammatory strategies. Open Inflamm. J. 5 (2012), 1–9, 10.2174/1875041901205010001.
101. Takagaki, A., Nanjo, F., Metabolism of (-)-epigallocatechin gallate by rat intestinal flora. J. Agric. Food Chem. 58 (2010), 1313–1321, 10.1021/jf903375s.
102. Thygesen, K., Alpert, J.S., White, H.D., Universal definition of myocardial infarction. Eur. Heart J. 28 (2007), 2525–2538, 10.1093/eurheartj/ehm355.
103. Townsend, P.A., Scarabelli, T.M., Pasini, E., Gitti, G., Menegazzi, M., Suzuki, H., Knight, R.A., Latchman, D.S., Stephanou, A., Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. FASEB J. 18 (2004), 1621–1623, 10.1096/fj.04-1716fje.
104. Unno, T., Takeo, T., Absorption of (-)-epigallocatechin gallate into the circulation system of rats. Biosci. Biotechnol. Biochem. 59 (1995), 1558–1559, 10.1271/bbb.59.1558.
105. Wais, U., Jackson, A.W., He, T., Zhang, H., Nanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles. Nanoscale 8 (2016), 1746–1769, 10.1039/c5nr07161e.
106. Wang, T., Xiang, Z., Wang, Y., Li, X., Fang, C., Song, S., Li, C., Yu, H., Wang, H., Yan, L., Hao, S., Wang, X., Sheng, J., (-)-Epigallocatechin gallate targets notch to attenuate the inflammatory response in the immediate early stage in human macrophages. Front. Immunol., 8, 2017, 433, 10.3389/fimmu.2017.00433.
107. Widlansky, M.E., Hamburg, N.M., Anter, E., Holbrook, M., Kahn, D.F., Elliott, J.G., Keaney, J.F., Vita, J.A., Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J. Am. Coll. Nutr. 26 (2007), 95–102, 10.1080/07315724.2007.10719590.
108. Widmer, R.J., Freund, M.A., Flammer, A.J., Sexton, J., Lennon, R., Romani, A., Mulinacci, N., Vinceri, F.F., Lerman, L.O., Lerman, A., Beneficial effects of polyphenol-rich olive oil in patients with early atherosclerosis. Eur. J. Nutr. 52 (2012), 1223–1231, 10.1007/s00394-012-0433-2.
109. Wolfram, S., Raederstorff, D., Wang, Y., Teixeira, S.R., Elste, V., Weber, P., TEAVIGO (Epigallocatechin Gallate) supplementation prevents obesity in rodents by reducing adipose tissue mass. Ann. Nutr. Metab. 49 (2005), 54–63, 10.1159/000084178.
110. Wynn, T., Cellular and molecular mechanisms of fibrosis. J. Pathol. 214 (2008), 199–210, 10.1002/path.2277.
111. Xu, X., Pan, J., Zhou, X., Amelioration of lipid profile and level of antioxidant activities by epigallocatechin-gallate in a rat model of atherogenesis. Heart Lung Circ. 23 (2014), 1194–1201, 10.1016/j.hlc.2014.05.013.
112. Yang, Y., Qin, Y.J., Yip, Y.W.Y., Chan, K.P., Chu, K.O., Chu, W.K., Ng, T.K., Pang, C.P., Chan, S.O., Green tea catechins are potent anti-oxidants that ameliorate sodium iodate-induced retinal degeneration in rats. Sci. Rep., 6, 2016, 29546, 10.1038/srep29546.
113. Yao, Y.F., Liu, X., Li, W.J., Shi, Z.W., Yan, Y.X., Wang, L.F., Chen, M., Xie, M.Y., (-)-Epigallocatechin-3-gallate alleviates doxorubicin-induced cardiotoxicity in sarcoma 180 tumor-bearing mice. Life Sci. 180 (2017), 151–159, 10.1016/j.lfs.2016.12.004.
114. Yin, C., Yang, L., Zhao, H., Li, C.P., Improvement of antioxidant activity of egg white protein by phosphorylation and conjugation of epigallocatechin gallate. Food Res. Int. 64 (2014), 855–863, 10.1016/j.foodres.2014.08.020.
115. Yin, J., Huang, F., Yi, Y., Yin, L., Peng, D., EGCG attenuates atherosclerosis through the Jagged-1/Notch pathway. Int. J. Mol. Med. 37 (2016), 398–406, 10.3892/ijmm.2015.2422.
116. Yoon, J.Y., Kwon, H.H., Min, S.U., Thiboutot, D.M., Suh, D.H., Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. J. Invest. Dermatol. 133 (2013), 429–440, 10.1038/jid.2012.292.
117. Yoshino, K., Suzuki, M., Sasaki, K., Miyase, T., Sano, M., Formation of antioxidants from (-)-epigallocatechin gallate in mild alkaline fluids, such as authentic intestinal juice and mouse plasma. J. Nutr. Biochem. 10 (1999), 223–229, 10.1016/S0955-2863(98)00103-X.
118. You, H., Wei, L., Sun, W.L., Wang, L., Yang, Z.L., Liu, Y., Zheng, K., Wang, Y., Zhang, W.J., The green tea extract epigallocatechin-3-gallate inhibits irradiation-induced pulmonary fibrosis in adult rats. Int. J. Mol. Med. 34 (2014), 92–102, 10.3892/ijmm.2014.1745.
119. Yu, D., Zhang, C., Zhao, S., Zhang, S., Zhang, H., Cai, S., Shao, R., He, H., The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated by the PI3K/Akt/Smad pathway. Acta Pharmacol. Sin. 36 (2015), 473–482, 10.1038/aps.2014.155.
120. Yu, N.H., Pei, H., Huang, Y.P., Li, Y.F., (-)-Epigallocatechin-3-gallate inhibits arsenic-induced inflammation and apoptosis through suppression of oxidative stress in mice. Cell. Physiol. Biochem. 41 (2017), 1788–1800, 10.1159/000471911.
121. Zakynthinos, E., Pappa, N., Inflammatory biomarkers in coronary artery disease. J. Cardiol. 53 (2009), 317–333, 10.1016/j.jjcc.2008.12.007.
122. Zaveri, N.T., Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci. 78 (2006), 2073–2080, 10.1016/j.lfs.2005.12.006.
123. Zeng, X., Tan, X., Epigallocatechin-3-gallate and zinc provide anti-apoptotic protection against hypoxia/reoxygenation injury in H9c2 rat cardiac myoblast cells. Mol. Med. Rep. 12 (2015), 1850–1856, 10.3892/mmr.2015.3603.
124. Zhang, F., Li, N., Jiang, L., Chen, L., Huang, M., Neuroprotective effects of (-)-epigallocatechin-3-gallate against focal cerebral ischemia/reperfusion injury in rats through attenuation of inflammation. Neurochem. Res. 40 (2015), 1691–1698, 10.1007/s11064-015-1647-5.
125. Zhang, J., Nie, S., Wang, S., Nanoencapsulation enhances epigallocatechin-3-gallate stability and its antiatherogenic bioactivities in macrophages. J. Agric. Food Chem. 61 (2013), 9200–9209, 10.1021/jf4023004.
126. Zhang, L., Zhang, Z.K., Liang, S., Epigallocatechin-3-gallate protects retinal vascular endothelial cells from high glucose stress in vitro via the MAPK/ERK-VEGF pathway. Genet. Mol. Res. 15 (2016), 1–11, 10.4238/gmr.15027874.